People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Health Care, Healthtech, Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nuvaira, Inc. | — | Other Health Care | Series C | $177.8M | $191.7M | 2013 |
| Cala Health, Inc. | — | Healthtech | Series C | $166.1M | $369.8M | 2016 |
| Allay Therapeutics, Inc. | — | Pharma | Series C | $162.6M | $323.2M | 2019 |
| Gi Dynamics, Inc. | — | Biotechnology | Series B | $90.1M | $85.7M | 2009 |
| Apreo Health, Inc. | — | Healthtech | Series C | $81.8M | $512.9M | 2025 |
| MediSix Therapeutics, Inc. | — | Biotechnology | Series B | $42.9M | $646.8M | 2019 |
Michael A. Carusi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael A. Carusi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| MARK A. DEEM | 3 | 3 |
| Hanson S. Gifford III | 2 | 11 |
| Michael Carusi | 2 | 7 |
| Kirk Nielsen | 1 | 13 |
| Timothy J. Barberich | 1 | 7 |
| John Kuelper | 1 | 6 |
| DANIEL MOORE | 1 | 6 |
| Timothy Barberich | 1 | 6 |
| Renee Ryan | 1 | 6 |
| James Lee | 1 | 5 |
| Juan-Pablo Mas | 1 | 5 |
| STACY ENXING SENG | 1 | 5 |
| David Stassen | 1 | 5 |
| Henry A. Plain | 1 | 5 |
| Hank Plain | 1 | 5 |
| Mark Deem | 1 | 5 |
| Nicole Walker | 1 | 4 |
| ROBERT PAULL | 1 | 4 |
| NEIL TIWARI | 1 | 4 |
| Dave Stassen | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.